07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

Multipotent bone marrow-derived stem cells: Phase II started

AlloCure began the double-blind, placebo-controlled, U.S. Phase II ACT-AKI trial to evaluate a single dose of AC607 in 200 cardiac surgery patients who experienced kidney injury within 24 hours of surgery. The product has Fast...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

AlloCure board of directors update

AlloCure Inc., Burlington, Mass.   Business: Renal, Gene/Cell therapy   Appointed: Mette Agger, managing partner of Lundbeckfond Ventures   ...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Financial News

AlloCure completes venture financing

AlloCure Inc., Burlington, Mass.   Business: Renal, Gene/Cell therapy   Date completed: 4/2/12   Type: Venture financing   Raised: $25 million   Investors: Lundbeckfond Ventures; SV Life Sciences; Novo A/S   ...
01:09 , Apr 3, 2012 |  BC Extra  |  Financial News

AlloCure raises $25 million in series B

AlloCure Inc. (Burlington, Mass.) raised $25 million in a series B round. New investor Lundbeckfond Ventures joined existing investors SV Life Sciences and Novo A/S in the round. AlloCure plans to start Phase II testing...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

Multipotent bone marrow-derived stem cells regulatory update

FDA granted Fast Track designation for AlloCure's AC607 to treat acute kidney injury (AKI). The company plans to start Phase II testing of the formulation of allogeneic bone marrow-derived mesenechymal stem cells this half. AlloCure...
08:00 , Dec 12, 2011 |  BC Week In Review  |  Clinical News

Multipotent bone marrow-derived stem cells: Phase I data

An open-label, U.S. Phase I trial in 16 patients who underwent coronary artery bypass graft (CABG) and/or heart valve surgery and who were at high risk of developing AKI showed that intra-aortic infusions of AC607...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Company News

AlloCure management update

AlloCure Inc., Burlington, Mass.   Business: Renal, Gene/Cell therapy   Hired: Kevin Heyeck as CBO, formerly VP of business development at Vitae Pharmaceuticals Inc.   ...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Company News

AlloCure management update

AlloCure Inc., Burlington, Mass.   Business: Renal, Gene/Cell therapy   Hired: Robert Brenner as president and CEO, formerly SVP of medical affairs at AMAG Pharmaceuticals Inc.   ...
07:00 , Jun 29, 2009 |  BioCentury  |  Finance

Ebb & Flow

Novo's crossover ambitions Novo A/S has tripled its commitment to life sciences venture investment from roughly $100 million to $300 million annually. Last week, Novo unveiled its evergreen Novo Growth Equity fund, which will invest $200...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Company News

AlloCure board of directors update

AlloCure Inc., Salt Lake City, Utah   Business: Renal, Gene/Cell therapy   Appointed: Lutz Giebel, a managing partner at SV Life Sciences LLP; Thomas Dyrberg, a senior partner at Novo A/S   ...